Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 32
Filter
2.
Can J Neurol Sci ; 46(3): 269-274, 2019 05.
Article in English | MEDLINE | ID: mdl-30890199

ABSTRACT

After five positive randomized controlled trials showed benefit of mechanical thrombectomy in the management of acute ischemic stroke with emergent large-vessel occlusion, a multi-society meeting was organized during the 17th Congress of the World Federation of Interventional and Therapeutic Neuroradiology in October 2017 in Budapest, Hungary. This multi-society meeting was dedicated to establish standards of practice in acute ischemic stroke intervention aiming for a consensus on the minimum requirements for centers providing such treatment. In an ideal situation, all patients would be treated at a center offering a full spectrum of neuroendovascular care (a level 1 center). However, for geographical reasons, some patients are unable to reach such a center in a reasonable period of time. With this in mind, the group paid special attention to define recommendations on the prerequisites of organizing stroke centers providing medical thrombectomy for acute ischemic stroke, but not for other neurovascular diseases (level 2 centers). Finally, some centers will have a stroke unit and offer intravenous thrombolysis, but not any endovascular stroke therapy (level 3 centers). Together, these level 1, 2, and 3 centers form a complete stroke system of care. The multi-society group provides recommendations and a framework for the development of medical thrombectomy services worldwide.


Subject(s)
Stroke/therapy , Brain Ischemia/complications , Brain Ischemia/therapy , Endovascular Procedures/methods , Humans , Stroke/etiology , Thrombectomy/methods
4.
Int J Mol Sci ; 19(12)2018 Nov 26.
Article in English | MEDLINE | ID: mdl-30486239

ABSTRACT

Common wheat originated from interspecific hybridization between cultivated tetraploid wheat and its wild diploid relative Aegilops tauschii followed by amphidiploidization. This evolutionary process can be reproduced artificially, resulting in synthetic hexaploid wheat lines. Here we performed RNA sequencing (RNA-seq)-based bulked segregant analysis (BSA) using a bi-parental mapping population of two synthetic hexaploid wheat lines that shared identical A and B genomes but included with D-genomes of distinct origins. This analysis permitted identification of D-genome-specific polymorphisms around the Net2 gene, a causative locus to hybrid necrosis. The resulting single nucleotide polymorphisms (SNPs) were classified into homoeologous polymorphisms and D-genome allelic variations, based on the RNA-seq results of a parental tetraploid and two Ae. tauschii accessions. The difference in allele frequency at the D-genome-specific SNP sites between the contrasting bulks (ΔSNP-index) was higher on the target chromosome than on the other chromosomes. Several SNPs with the highest ΔSNP-indices were converted into molecular markers and assigned to the Net2 chromosomal region. These results indicated that RNA-seq-based BSA can be applied efficiently to a synthetic hexaploid wheat population to permit molecular marker development in a specific chromosomal region of the D genome.


Subject(s)
Chromosome Segregation/genetics , Chromosomes, Plant/genetics , Genome, Plant , Sequence Analysis, RNA/methods , Tetraploidy , Triticum/genetics , Chromosome Mapping , Genetic Markers , Polymorphism, Single Nucleotide/genetics
8.
Sci Rep ; 5: 7979, 2015 Jan 27.
Article in English | MEDLINE | ID: mdl-25623281

ABSTRACT

Cancers are composed of heterogeneous combinations of cells that exhibit distinct phenotypic characteristics and proliferative potentials. Because most cancers have a clonal origin, cancer stem cells (CSCs) must generate phenotypically diverse progenies including mature CSCs that can self-renew indefinitely and differentiated cancer cells that possess limited proliferative potential. However, no convincing evidence exists to suggest that only single CSCs are representative of patients' tumors. To investigate the CSCs' diversity, we established 4 subclones from a glioblastoma patient. These subclones were subsequently propagated and analyzed. The morphology, the self-renewal and proliferative capacities of the subclones differed. Fluorescence-activated cell sorting and cDNA-microarray analyses revealed that each subclone was composed of distinct populations of cells. Moreover, the sensitivities of the subclones to an inhibitor of epidermal growth factor receptor were dissimilar. In a mouse model featuring xenografts of the subclones, the progression and invasion of tumors and animal survival were also different. Here, we present clear evidence that a brain tumor contains heterogeneous subclones that exhibit dissimilar morphologies and self-renewal and proliferative capacities. Our results suggest that single cell-derived subclones from a patient can produce phenotypically heterogeneous self-renewing progenies in both in vitro and in vivo settings.


Subject(s)
Brain Neoplasms/pathology , Glioblastoma/pathology , Animals , Antigens, CD/metabolism , Brain Neoplasms/mortality , Collagen Type I/metabolism , Collagen Type I, alpha 1 Chain , Disease Models, Animal , ErbB Receptors/antagonists & inhibitors , ErbB Receptors/metabolism , Gefitinib , Glioblastoma/mortality , Humans , Insulin-Like Growth Factor Binding Proteins/metabolism , Kaplan-Meier Estimate , Mice , Mice, Inbred NOD , Mice, SCID , Middle Aged , Oligonucleotide Array Sequence Analysis , Protein Kinase Inhibitors/toxicity , Quinazolines/toxicity , Signal Transduction/drug effects , Transplantation, Heterologous , Tumor Cells, Cultured
9.
Diagn Pathol ; 6: 119, 2011 Dec 06.
Article in English | MEDLINE | ID: mdl-22145948

ABSTRACT

A 55-year-old man presented with a large tumor in his lateral ventricles. Magnetic resonance imaging revealed disseminated lesions in the third and fourth ventricles at the time of diagnosis. The patient underwent a partial removal of the tumor in the lateral ventricles. Histologically, the surgical specimens showed glioneuronal differentiation with ganglion or ganglioid cells, Rosenthal fibers, oligodendroglia-like honeycomb appearances, a spongy pattern, perivascular pseudorosettes, and many hyalinized blood vessels. Papillary structure was not observed. The neuronal component showed a moderately high labeling index of Ki-67/MIB-1. We diagnosed this tumor as atypical intraventricular glioneuronal tumor. The disseminated lesions disappeared after chemoradiation therapy with temozolomide, and the residual tumors in the lateral ventricles remained stable for 3 years after the surgery. We discuss the pathological diagnosis, therapy and clinical course with review of the literatures.


Subject(s)
Cerebral Ventricle Neoplasms/pathology , Cerebral Ventricles/pathology , Ganglioglioma/pathology , Ki-67 Antigen/metabolism , Antineoplastic Agents, Alkylating/therapeutic use , Biomarkers, Tumor/metabolism , Cerebral Ventricle Neoplasms/surgery , Cerebral Ventricle Neoplasms/therapy , Chemoradiotherapy, Adjuvant , Dacarbazine/analogs & derivatives , Dacarbazine/therapeutic use , Diagnosis, Differential , Ganglioglioma/surgery , Ganglioglioma/therapy , Humans , Immunohistochemistry , Magnetic Resonance Imaging , Male , Middle Aged , Radiotherapy, Intensity-Modulated , Temozolomide , Treatment Outcome
10.
Cytotherapy ; 13(6): 675-85, 2011 Jul.
Article in English | MEDLINE | ID: mdl-21231804

ABSTRACT

BACKGROUND AIMS: Transplantation of mesenchymal stromal cells (MSC) derived from bone marrow (BM) or adipose tissue is expected to become a cell therapy for stroke. The present study compared the therapeutic potential of adipose-derived stem cells (ASC) with that of BM-derived stem cells (BMSC) in a murine stroke model. METHODS: ASC and BMSC were isolated from age-matched C57BL/6J mice. These MSC were analyzed for growth kinetics and their capacity to secrete trophic factors and differentiate toward neural and vascular cell lineages in vitro. For in vivo study, ASC or BMSC were administrated intravenously into recipient mice (1 × 10(5) cells/mouse) soon after reperfusion following a 90-min middle cerebral artery occlusion. Neurologic deficits, the degree of infarction, expression of factors in the brain, and the fate of the injected cells were observed. RESULTS: ASC showed higher proliferative activity with greater production of vascular endothelial cell growth factor (VEGF) and hepatocyte growth factor (HGF) than BMSC. Furthermore, in vitro conditions allowed ASC to differentiate into neural, glial and vascular endothelial cells. ASC administration showed remarkable attenuation of ischemic damage, although the ASC were not yet fully incorporated into the infarct area. Nonetheless, the expression of HGF and angiopoietin-1 in ischemic brain tissue was significantly increased in ASC-treated mice compared with the BMSC group. CONCLUSIONS: Compared with BMSC, ASC have great advantages for cell preparation because of easier and safer access to adipose tissue. Taken together, our findings suggest that ASC would be a more preferable source for cell therapy for brain ischemia than BMSC.


Subject(s)
Adipose Tissue/cytology , Bone Marrow Cells/cytology , Mesenchymal Stem Cells/cytology , Stroke/therapy , Animals , Brain Ischemia/metabolism , Brain Ischemia/therapy , Cell- and Tissue-Based Therapy , Hepatocyte Growth Factor/metabolism , Male , Mesenchymal Stem Cell Transplantation , Mice , Mice, Inbred C57BL , Stroke/metabolism , Vascular Endothelial Growth Factor A/metabolism
11.
Hypertens Res ; 33(7): 703-7, 2010 Jul.
Article in English | MEDLINE | ID: mdl-20485441

ABSTRACT

Release of neutrophil elastase is one of the harmful inflammatory reactions in acute cerebral ischemia. Therefore, inhibition of elastase released from neutrophils could be a useful strategy for the treatment of acute stroke. To evaluate this hypothesis, the effect of sivelestat, a selective neutrophil elastase inhibitor was examined in a mouse model of focal ischemia. The results obtained indicate that sivelestat reduced brain edema and vascular permeability, and subsequently improved the neurological deficit in an acute focal ischemia. The architecture of microvessels was analyzed by identifying vascular endothelial cells, which were prelabeled by injecting fluorescein-labeled Griffonia simplicifolia lectin I-isolectin B4 into a tail vein. Most of the microvessels in the infarcted area were structurally destroyed in the control group. In sharp contrast, microvessels in the boundary zone were well maintained in the sivelestat-treated group. Moreover, the expression of angiopoietin-1 was elevated at the ischemic margin in the sivelestat-treated group. Furthermore, the neutrophil elastase inhibitor rescued human brain microvascular endothelial cells in culture from neutrophil elastase-induced damage. These results suggest that neutrophil elastase inhibition could protect blood-brain barrier function in acute cerebral ischemia by augmentation of angiopoietin-1 expression and survival of endothelial cells.


Subject(s)
Brain Edema/drug therapy , Capillary Permeability/drug effects , Glycine/analogs & derivatives , Hypoxia-Ischemia, Brain/drug therapy , Proteinase Inhibitory Proteins, Secretory/therapeutic use , Sulfonamides/therapeutic use , Acute Disease , Angiopoietin-1/analysis , Animals , Blood-Brain Barrier/drug effects , Cells, Cultured , Glycine/therapeutic use , Humans , Leukocyte Elastase/antagonists & inhibitors , Male , Mice , Mice, Inbred C57BL , Microvessels/drug effects
12.
Pathol Oncol Res ; 15(2): 301-5, 2009 Jun.
Article in English | MEDLINE | ID: mdl-18802789

ABSTRACT

A 26-year-old woman presented with rapid tumor growth in her left frontal lobe during 9 years of observation. Operative findings revealed a massive tumor connected to gelatinous, transparent membranous tissue (MT), which extended from the paraventricular zone and continued into the lateral ventricle. Histological diagnosis was atypical neurocytoma. Immunohistochemical analyses revealed that the tumor was strongly positive for not only neural markers but also a glial marker, while the MT was positive for a neural marker. The Ki-67/MIB-1 labeling index was 9.1% in the tumor body and 0% in the MT. Musashi 1, a marker of neural stem cells, was strongly positive in both the tumor body and the MT. We speculate that the tumor growth was due to a rapid decline of the Musashi 1-positive cells to glial differentiation. These cells may be candidates for the origin of the tumor.


Subject(s)
Brain Neoplasms/metabolism , Brain Neoplasms/pathology , Nerve Tissue Proteins/metabolism , Neurocytoma/metabolism , Neurocytoma/pathology , RNA-Binding Proteins/metabolism , Adolescent , Brain Neoplasms/surgery , Female , Humans , Immunoenzyme Techniques , Ki-67 Antigen/metabolism , Neurocytoma/surgery , Tomography, X-Ray Computed
13.
Surg Neurol ; 70(4): 421-4; discussion 424, 2008 Oct.
Article in English | MEDLINE | ID: mdl-18291446

ABSTRACT

BACKGROUND: Aneurysms arising from the distal portion of the SCA are relatively rare. A case is presented of an aneurysm arising from the cortical segment of the SCA. CASE DESCRIPTION: A 45-year-old woman was admitted to our institution because of severe headache. Radiological examination revealed SAH caused by rupture of the aneurysm located in the cortical segment of the SCA and was treated successfully with coil embolization. CONCLUSIONS: This type of aneurysms may be difficult to treat surgically because of its inaccessibility and of the common difficulty in preserving the involved parent artery. In view of the previously reported cases, these peripheral aneurysms of the SCA often have undefinable necks, as is shown in our case, which makes a reconstructive endovascular and/or surgical technique more or less difficult. However, the overall outcome is almost always favorable, even if surgical treatment results in proximal parent artery occlusion or trapping with surgical clips. These results imply that an equivalent endovascular approach to these rare lesions can be an effective alternative method of management.


Subject(s)
Cerebellum/blood supply , Embolization, Therapeutic , Intracranial Aneurysm/diagnostic imaging , Intracranial Aneurysm/therapy , Cerebral Angiography , Female , Humans , Middle Aged , Tomography, X-Ray Computed
14.
J Biol Chem ; 283(16): 10958-66, 2008 Apr 18.
Article in English | MEDLINE | ID: mdl-18292095

ABSTRACT

A cancer stem cell population in malignant brain tumors takes an essential part in brain tumor initiation, growth, and recurrence. Growth factors, such as epidermal growth factor, fibroblast growth factor-2, vascular endothelial growth factor, platelet-derived growth factor, and hepatocyte growth factor, are shown to support the proliferation of neural stem cells and also may play key roles in gliomagenesis. However, the responsible growth factor(s), which controls maintenance of brain tumor stem cells, is not yet uncovered. We have established three cancer stem cell lines from human gliomas. These cells were immunoreactive with the neuronal progenitor markers, nestin and CD133, and established tumors that closely resembled the features of original tumor upon transplantation into mouse brain. Three cell lines retained their self-renewal ability and proliferation only in the presence of epidermal growth factor (>2.5 ng/ml). In sharp contrast, other growth factors, including fibroblast growth factor-2, failed to support maintenance of these cells. The tyrosine kinase inhibitors of epidermal growth factor signaling (AG1478 and gefitinib) suppressed the proliferation and self-renewal of these cells. Gefitinib inhibited phosphorylation of epidermal growth factor receptor as well as Akt kinase and extracellular signal-regulated kinase 1/2. Flow cytometric analysis revealed that epidermal growth factor concentration-dependently increased the population of CD133-positive cells. Gefitinib significantly reduced CD133-positive fractions and also induced their apoptosis. These results indicate that maintenance of human brain tumor stem cells absolutely requires epidermal growth factor and that tyrosine kinase inhibitors of epidermal growth factor signaling potentially inhibit proliferation and induce apoptosis of these cells.


Subject(s)
Brain Neoplasms/metabolism , Epidermal Growth Factor/physiology , Gene Expression Regulation, Neoplastic , Stem Cells/metabolism , AC133 Antigen , Antigens, CD/biosynthesis , Enzyme Inhibitors/pharmacology , Gefitinib , Glycoproteins/biosynthesis , Humans , Intercellular Signaling Peptides and Proteins/metabolism , Models, Biological , Peptides , Phosphorylation , Protein-Tyrosine Kinases/antagonists & inhibitors , Quinazolines/pharmacology , Signal Transduction , Tumor Cells, Cultured , Tyrphostins/pharmacology
15.
Neurol Med Chir (Tokyo) ; 47(12): 550-4, 2007 Dec.
Article in English | MEDLINE | ID: mdl-18159139

ABSTRACT

A 33-year-old woman presented with a rare intracranial pial arteriovenous fistula manifesting as monoparesis and hypesthesia of the right lower extremity. Computed tomography demonstrated an approximately 10-mm diameter subcortical hematoma in the left postcentral gyrus. Two months after suffering the ictus, angiography demonstrated a pial arteriovenous fistula in the late arterial phase fed by the left paracentral artery and drained into the left precentral vein. No nidus or dural arteriovenous fistula was detected. Left parietal craniotomy was performed and the pial arteriovenous fistula was extirpated by electrocoagulation. Intraoperative angiography demonstrated disappearance of the fistula. She experienced no postoperative neurological deterioration, but hypesthesia of the right leg persisted. Obliteration of the pial arteriovenous fistula was reconfirmed by postoperative angiography. She suffered no rebleeding episodes during the 36-month follow-up period. Pial arteriovenous fistula causing mild symptoms should be treated by flow disconnection because the direct arteriovenous shunt and attendant high blood flow usually results in huge venous varices. To determine whether direct surgery or endovascular treatment is appropriate, the position and shape of the lesion must be known.


Subject(s)
Arteriovenous Fistula/diagnosis , Arteriovenous Fistula/therapy , Central Nervous System Vascular Malformations/diagnosis , Central Nervous System Vascular Malformations/therapy , Pia Mater/blood supply , Adult , Female , Humans
16.
Brain Res ; 1154: 215-24, 2007 Jun 18.
Article in English | MEDLINE | ID: mdl-17482584

ABSTRACT

BACKGROUND AND PURPOSE: Recently, fasudil, a Rho kinase (ROCK) inhibitor, was reported to prevent cerebral ischemia in vivo by increasing cerebral blood flow and inhibiting inflammatory responses. However, it is uncertain whether a ROCK inhibitor can directly protect neurons against ischemic damage. Our purpose was to evaluate both the involvement of ROCK activity in ischemic neuronal damage and any direct neuroprotective effect of fasudil against cerebral infarction. METHODS: In vivo, focal cerebral ischemia was induced by permanent middle cerebral artery occlusion in mice, and the resulting infarction was evaluated 24 h later. ROCK expression and activity were assessed using Western blotting and immunohistochemistry. In vitro, the effects of fasudil and hydroxyfasudil (a main metabolite of fasudil) were examined on oxygen-glucose deprivation (OGD)-induced PC12 cell death and on glutamate-induced neurotoxicity in primary cerebral neuronal culture. RESULTS: ROCK expression and activity increased in the striatum, especially in axons, in the early phase of ischemia. Fasudil reduced this ROCK activity and protected against cerebral infarction in vivo. Hydroxyfasudil inhibited OGD-induced PC12 cell death, and fasudil and hydroxyfasudil each attenuated glutamate-induced neurotoxicity in vitro. CONCLUSIONS: These findings indicate that ROCK plays a pivotal role in the mechanism underlying ischemic neuronal damage and that a direct effect of fasudil on neurons may be partly responsible for its protective effects against such damage.


Subject(s)
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine/analogs & derivatives , Brain Ischemia/drug therapy , Brain Ischemia/pathology , Neurons/drug effects , Neuroprotective Agents/therapeutic use , 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine/therapeutic use , Animals , Cell Survival/drug effects , Dose-Response Relationship, Drug , Drug Interactions , Glucose/deficiency , Glutamic Acid/pharmacology , Hypoxia , In Vitro Techniques , Intracellular Signaling Peptides and Proteins/metabolism , Male , Mice , Neurofilament Proteins/metabolism , PC12 Cells , Protein Serine-Threonine Kinases/metabolism , Rats , Time Factors , rho-Associated Kinases
17.
Clin Neurol Neurosurg ; 107(2): 117-22, 2005 Feb.
Article in English | MEDLINE | ID: mdl-15708226

ABSTRACT

BACKGROUND: Dissecting aneurysm of the posterior inferior cerebellar artery (PICA) uninvolved with the vertebral artery is rare. The exact pathohistological diagnosis might result in 'unknown' because the underlying pathoanatomical features are, for a variety of reasons, not always identified. CASE DESCRIPTION: We report herein two cases of dissecting aneurysm harbored in different segments of the distal posterior inferior cerebellar artery. In our cases, after trapping the PICA at both just proximal and distal to the aneurysm, the abnormal portion was successfully resected with/without an end-to-end anastomosis. The first patient made a good recovery, while the other died 2 days after the surgery. Although its pathogenetic etiology was unidentified in the second case, the formation of dissecting aneurysm had resulted from a segmental mediolytic arteriopathy in the first case. CONCLUSION: This is the first report of a segmental mediolytic arteriopathy possibly being identified as causing an isolated dissecting aneurysm at this site.


Subject(s)
Aortic Dissection/etiology , Arteritis/complications , Cerebellum/blood supply , Tunica Media/pathology , Aortic Dissection/physiopathology , Aortic Dissection/therapy , Female , Humans , Male , Middle Aged , Treatment Outcome
18.
J Cereb Blood Flow Metab ; 25(6): 722-9, 2005 Jun.
Article in English | MEDLINE | ID: mdl-15716855

ABSTRACT

Previous studies have shown that 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) protect the brain against ischemic injury by upregulating endothelial nitric oxide synthase (eNOS). Here, we tested the hypothesis that statins provide additional beneficial effects by also upregulating endogenous tissue plasminogen activator (tPA) and enhancing clot lysis in a mouse model of embolic focal ischemia. Heterologous blood clots (0.2 mm) were injected into the distal internal carotid artery to occlude blood flow in the middle cerebral artery territory after long-term (14 days) simvastatin, atorvastatin or vehicle treatment. Ischemic lesion volume, neurologic deficits, as well as residual blood clots were measured at 22 h. Reverse transcription-polymerase chain reaction assessed mRNA levels of eNOS, tPA, and the endogenous plasminogen activator inhibitor PAI-1. Ischemic lesion volumes and neurologic deficits were significantly reduced in wild-type mice by both simvastatin and atorvastatin. Statins increased eNOS and tPA mRNA levels but did not change mRNA levels of PAI-1. In eNOS knockout mice, atorvastatin reduced the volume of ischemic tissue and improved neurologic outcomes after arterial occlusion by blood clot emboli. In contrast, statins did not have protective effects in tPA knockout mice after embolic focal ischemia, but only in a filament model where focal ischemia was achieved via mechanical occlusion. These results suggest that statins protect against stroke by multiple mechanisms involving both eNOS and tPA. The involvement of each pathway may be revealed depending on the choice of experimental stroke model.


Subject(s)
Brain Ischemia/drug therapy , Brain Ischemia/metabolism , Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology , Nitric Oxide Synthase/metabolism , Simvastatin/pharmacology , Tissue Plasminogen Activator/metabolism , Animals , Atorvastatin , Disease Models, Animal , Heptanoic Acids/pharmacology , Intracranial Embolism/drug therapy , Intracranial Embolism/metabolism , Male , Mice , Mice, Inbred Strains , Mice, Knockout , Neuroprotective Agents/pharmacology , Nitric Oxide Synthase/genetics , Nitric Oxide Synthase Type II , Nitric Oxide Synthase Type III , Pyrroles/pharmacology , Stroke/drug therapy , Stroke/metabolism , Tissue Plasminogen Activator/genetics
19.
AJNR Am J Neuroradiol ; 25(8): 1403-8, 2004 Sep.
Article in English | MEDLINE | ID: mdl-15466341

ABSTRACT

BACKGROUND AND PURPOSE: Cerebral hyperperfusion syndrome has been increasingly reported as a complication of carotid angioplasty and stent placement. The aim of the present study was to determine significant predictors of hyperperfusion phenomenon after carotid angioplasty and stent placement. METHODS: We retrospectively reviewed 30 consecutive patients with unilateral severe carotid stenosis who underwent angioplasty and stent placement. Resting cerebral blood flow (CBF) and cerebral vasoreactivity (CVR) to acetazolamide challenge were quantitatively measured to evaluate cerebral hemodynamic reserve. Split-dose [(123)I] iodoamphetamine single photon emission CT (SPECT) was performed before and 7 days after carotid angioplasty and stent placement. Technetium-99m hexamethylpropyleneamine oxime (HMPAO) SPECT was performed immediately after the procedure. RESULTS: Three patients had cerebral hyperperfusion phenomenon immediately after angioplasty and stent placement, as shown by HMPAO SPECT: One developed status epilepticus 2 weeks after the procedure. Significant predictors of hyperperfusion included patient age, pretreatment CVR, and pretreatment asymmetry index ([ipsilateral resting CBF/contralateral resting CBF] x 100). Variables determined not to be significant risk factors included pretreatment resting CBF value, degree of carotid stenosis, and interval from the onset of ischemic symptoms. CONCLUSION: Significant predictors of hyperperfusion phenomenon after carotid angioplasty and stent placement included patient age, pretreatment CVR, and pretreatment asymmetry index. Pretreatment CBF measurements, including those obtained by quantifying CVR and performing SPECT immediately after the procedure may aid in identifying patients at risk and in initiating careful monitoring and control of blood pressure to prevent hyperperfusion syndrome.


Subject(s)
Angioplasty, Balloon/adverse effects , Carotid Stenosis/therapy , Cerebrovascular Disorders/etiology , Hyperemia/etiology , Stents/adverse effects , Acetazolamide , Aged , Aged, 80 and over , Amphetamines , Carotid Stenosis/diagnosis , Carotid Stenosis/diagnostic imaging , Carotid Stenosis/physiopathology , Cerebrovascular Circulation/drug effects , Female , Hemodynamics , Humans , Iodine Radioisotopes , Male , Middle Aged , Predictive Value of Tests , Radiopharmaceuticals , Retrospective Studies , Technetium Tc 99m Exametazime , Tomography, Emission-Computed, Single-Photon , Vasomotor System/drug effects
20.
Int J Mol Med ; 14(4): 633-40, 2004 Oct.
Article in English | MEDLINE | ID: mdl-15375594

ABSTRACT

Although injury of epithelial cells has been reported to be responsible for renal disease such as acute renal failure, its molecular mechanisms are largely unknown. As hypoxia has been postulated as the initial trigger of epithelial injury, we studied the molecular mechanisms of apoptosis induced by hypoxia in human renal epithelial cells. Severe hypoxia caused epithelial cell death, accompanied by a significant increase in LDH release (p<0.01). In addition, hypoxic treatment of epithelial cells resulted in a significant increase in apoptotic cells as assessed by cell morphology (p<0.01). The apoptotic change in epithelial cells under hypoxic condition was also confirmed by a significant increase in caspase-3-like activity and release of cytochrome c (p<0.01). The decrease in epithelial cell number was completely abolished by addition of a wide-spectrum caspase inhibitor, Z-VAD, rather than Z-DEVD, a specific caspase-3 inhibitor (p<0.01). Thus, we further studied the molecular mechanisms of apoptosis induced by hypoxia. Anti-apoptotic factors, Bcl-2 and Bcl-xL, were significantly decreased in epithelial cells under a hypoxic condition as assessed by Western blotting (p<0.01). In contrast, hypoxia did not alter their location. Of particular importance, translocation of a proapoptotic factor, Bax, from the cytoplasm to the mitochondrial membrane was observed in response to hypoxia, whereas total Bax protein was not changed by hypoxia. Overall, this study demonstrated that hypoxia caused epithelial cell death induced by caspase-3-like activity-dependent apoptosis. The pro-apoptotic mechanisms of hypoxia in epithelial cells largely depend on a significant decrease in Bcl-2 and Bcl-xL. In addition, the present results demonstrate that translocation of Bax from the cytosol to the mitochondrial membrane occurred under hypoxia, thereby leading to pathological tissue destruction.


Subject(s)
Apoptosis , Caspases/metabolism , Cell Hypoxia/physiology , Epithelial Cells/metabolism , Kidney/pathology , Proto-Oncogene Proteins c-bcl-2/metabolism , Caspase 3 , Cytochromes c/metabolism , Epithelial Cells/enzymology , Epithelial Cells/pathology , Humans , Kidney/enzymology , Kidney/metabolism , Signal Transduction , bcl-2-Associated X Protein , bcl-X Protein
SELECTION OF CITATIONS
SEARCH DETAIL
...